Dear colleagues, dear friends,

Clinical research is becoming increasingly challenging and complex, with ever-growing constraints for investigators, progressively more stringent regulations, and exponentially increasing costs for sponsors. As part of our academic mission, it is essential for GORTEC to preserve and strengthen our capabilities in order to effectively address all of these challenges.

In this context, GORTEC is optimizing its partnerships and improving its internal processes. A key element for the long-term sustainability of the group is our ability to remain at the forefront of innovation by creating new opportunities for collaboration with industry partners and diversifying our portfolio, particularly through the Early Assets Board.

At the same time, we are doing everything we can to optimize the conduct of each study, ensuring an appropriate balance between needs and resources, and, above all, whenever possible, simplifying everything that can be simplified in the protocol, CRF, monitoring procedures, and so on.

Driven by the extraordinary motivation and strong commitment of our investigators, together with the efficiency of our operational team, GORTEC is successfully adapting to the growing challenges facing clinical research and remains a leading international player in head and neck oncology, at the forefront of innovation in this field.